Effects of Nimesulide and Sodium Diclofenac on Interleukin-6, Interleukin-8, Proteoglycans and Prostaglandin E2 Production by Human Articular Chondrocytes in Vitro
Henrotin, Yves; Labasse, A. H.; Simonis, P. E.et al.
1999 • In Clinical and Experimental Rheumatology, 17 (2), p. 151-60
Effects of Nimesulide and Sodium Diclofenac on Interleukin-6, Interleukin-8, Proteoglycans and Prostaglandin E2 Production by Human Articular Chondrocytes in Vitro.pdf
[en] OBJECTIVES: The aim of this study was to investigate the effects of two nonsteroidal anti-inflammatory drugs (NSAIDs), nimesulide and sodium diclofenac, on the production of proteoglycans (PG), prostaglandin E2 (PGE2) and cytokines (IL-6 and IL-8) by human articular chondrocytes in vitro. METHODS: Enzymatically isolated chondrocytes were cultured under constant agitation in a well defined culture medium. Specific radioimmunoassays were used to quantify PG and PGE2 production. Cytokine production (IL-6 and IL-8) was assayed by enzyme amplified sensitivity immunoassays (EASIAs). RESULTS: At a concentration of 3 micrograms/ml, nimesulide did not affect the PG production by chondrocytes. This concentration was superior to the highest level of nimesulide found in the synovial fluid of patients with rheumatoid arthritis 3 hours after the last oral administration of nimesulide (100 mg twice daily for 7 days). At 6 micrograms/ml a significant reduction in the PG content was obtained in the cellular phase in 5 out of the 8 cultures investigated. No similar effect was observed in the culture supernatants. Above this concentration nimesulide inhibited PG production in a dose-dependent manner. At concentrations ranging from 0.005 to 1 microgram/ml diclofenac did not significantly alter PG production. At therapeutic concentrations PGE2 production was totally inhibited by nimesulide, thus suggesting that PG inhibition is not linked to PGE2 production. Nimesulide inhibited PGE2 production by unstimulated (IC50 = 6 ng/ml) and IL-1 beta-stimulated (IC50 = 6.9 ng/ml) chondrocytes. At these concentrations, PGE2 production was fully inhibited by diclofenac. Furthermore, both nimesulide and diclofenac at therapeutic concentrations significantly decreased spontaneous and IL-1 beta-stimulated IL-6 production by human chondrocytes, but did not modify IL-8 production. CONCLUSION: From the results of this study we conclude that nimesulide and diclofenac at therapeutic concentrations are potent inhibitors of PGE2 and IL-6 production while they do not modify proteoglycan or IL-8 production.
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
Labasse, A. H.
Simonis, P. E.
Zheng, S. X.
Dupont, Ginette ; Université de Liège - ULiège > Centres généraux > Centre de l'oxygène : Recherche et développement (C.O.R.D.)
Famaey, J. P.
Crielaard, Jean-Michel ; Université de Liège - ULiège > Département des sciences de la motricité > Evaluation et entraînement des aptitudes physiques
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Effects of Nimesulide and Sodium Diclofenac on Interleukin-6, Interleukin-8, Proteoglycans and Prostaglandin E2 Production by Human Articular Chondrocytes in Vitro
MARTEL-PELLETIER J, ZAFARULLAH M, KODAMA S, PELLETIER J-P: In vitro effects of interleukin-1 on synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage. J Rheumatol 1991; 18 (Suppl. 27): 80-4.
TIKU M, LIESCH J, ROBERTSON F: Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokines. J Immunol 1990; 145: 690-6.
GOLDRING MB, BIRKHEAD J, SANDELL LJ et al.: Interleukin-1 supresses expression of cartilage specific type II and IX collagens and increases type I and III collagens by human chondrocytes. J Clin Invest 1988; 82: 2026-37.
HENROTIN Y, DE GROOTE D, LABASSE A et al.: Effects of exogenous IL-1β, TNFα, IL-6, IL-8 and LIF on cytokines production by human articular chondrocytes. Osteoarthritis Cartilage 1996; 4: 163-73.
BRANDT K: Effects of non-steroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med 1987; 83: 29-34.
DINGLE JT: Cartilage maintenance in osteoarthritis: Interaction of cytokines, NSAID and prostaglandins in articular cartilage damage and repair. J Rheumatol 1991; 18: 30-7.
RASHAD S, REVELL P, HEMINGWAY A et al.: Effect of non-steroidal anti-inflammatory drugs on the course of OA. Lancet 1989; 2: 519-21.
PALMOSKI M, BRANDT K: Aspirin aggravates the degeneration of canine joint cartilage caused by immobilization. Arthritis Rheum 1982; 25: 1332-42.
DINGLE JT: Prostaglandins in human cartilage metabolism. J Lipid Mediators 1993; 6: 310-2.
DAVID MJ, VIGNON E, PESCHARD MJ et al.: Effect of non-steroidal anti-inflammatory drugs (NSAIDs) on glycosyltransferase activity from human osteoarthritic cartilage. Br J Rheumatol 1992; 31 (Suppl. 1): 13-7.
MAHMUD T, RAFI S, SCOTT DL et al.: Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 1996; 39: 1998-2003.
VIGNON E, MATHIEU P, LOUISOT P, RICHARD M: In vitro effect of nonsteroidal antiinflammatory drugs on proteoglycanase and collagenase activity in human osteoarthritic cartilage. Arthritis Rheum 1991; 34: 1332-7.
YAMADA H, KIKUCHI T, NEMOTO O et al.: Effects of indomethacin on production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by human chondrocytes. J Rheumatol 1996; 23: 1739-43.
FAMAEY J-P: In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview. Inflamm Res 1997; 46: 437-46.
BEVILACQUA M, VAGO T, BERETTA A: Nimesulide as an inhibitor of Superoxide anion (O2-) production by human polymorphonuclear leukocytes. In GENAZZANI AR, NAPPI G, FACCHINETTI F, MARTIGNONI E (Eds.): Pain and Reproduction, Parthenon Publishing Group 1993; 265-72.
CASOLARO V, MELIOTA S, MARINO O et al.: Nimesulide, a sulfonanilide nonsteroidal antiinflammatory drug, inhibits mediator release from human basophils and mast cells. J Pharmacol Exp Ther 1993; 267: 1375-85.
FERERIA SH: The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 1993; 46 (Suppl 1): 1-9.
BEVILACQUA M, VAGO T, BALDI G et al.: Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol 1994; 268: 415-23.
DALLEGRI F, OTTONELLO L, DAPINO P, BEVILACQUA M: The anti-inflammatory drug nimesulide rescues alpha-1-proteinase inhibitor from oxidative inactivation by phagocytosing neutrophils. Respiration 1992; 59: 1-4.
FACINO M, CARINI M, ALDINI G: Antioxidant activity of nimesulide and its main metabolites. Drugs 1993; 46 (Suppl. 1): 15-21.
DREISER RL, RIEBENFELD D: Nimesulide in the treatment of osteoarthritis. Double-blind studies in comparison with piroxicam, ketoprofen and placebo. Drugs 1993; 46 (Suppl. 1) 191-5.
PELLETIER J-P, MARTEL-PELLETIER J: Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs 1993;46 (Suppl. 1): 34-9.
MOSKOWITZ R, DAVIS W, SANMARCO J et al.: Experimentally induced degenerative joint lesions following partial menisectomy in the rabbit. Arthritis Rheum 1973; 16: 397-466.
DAVIS R, BROGDEN RN: Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431-54.
AZIZ K: Pharmacokinetic of diclofenac and misoprostol when administrated alone or as a combination product. Drugs 1993; 45 (Suppl. 1): 7-14.
GIROUD J-P, MATHE G, MEYNIEL G et al.: Pharmacologie clinique. Base de la thérapeutique. 2eme éd. AHFS (American Hospital Formulary service). Drug Information 1990; 1008.
GYSEN P, FRANCHIMONT P: Radioimmunoassay of human proteoglycans. J Immunoassay 1984; 5: 221-43.
VAITUKAITIS J, ROBBINS JB, NIESCHLAG E, ROSS GT: A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol Metab 1971; 33: 988-91.
GREENWOOD FC, HUNTER W, GLOVER J: The preparation of 125I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-24.
SERTEYN D, DEBY-DUPONT G, PINCEMAIL J et al.: Equine post-anesthetic myositis: thromboxane, prostacyclin and protaglandin E2 production. Vet Res Comm 1988; 12 : 219-26.
DE GROOTE D, ZANGERLE PF, GEVAERT Y et al.: Direct stimulation of cytokines (IL-1β, TNFα, IL-6, IL-2, IFN and GM-CSF) in whole blood. Comparison with isolated PBMC stimulation. Cytokine 1992; 4: 239-48.
LABARCA C, PAIGEN K: A simple, rapid and sensitive DNA assay procedure. Anal Biochem 1980; 102: 344-52.
ARNER EC, PRATTA MA: Independent effects of interleukin-1 on proteoglycan breakdown, proteoglycan synthesis and prostaglandin E2 release from cartilage in organ culture. Arthritis Rheum 1989; 32: 228-97.
BENTON HP, TYLER JA: Inhibition of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1988; 154: 421-8.
MITROVIC D, MCCALL E, FRONT P et al.: Antiinflammatory drugs, prostanoids and proteoglycan production by cultured bovine articular chondrocytes. Protaglandins 1984; 28: 417-34.
MALEMUD CJ, PAPAY RS, HASLER P, KAME GM: The effect of nonsteroidal anti-inflammatory drugs on cAMP-dependent protein kinase-mediated phosphorylation by human chondrocytes in culture. Clin Exp Rheumatol 1994; 12: 149-56.
VIGDAHL RL, TUKEY RH: Mechanism of action of novel anti-inflammatory drugs diflumidone and R-805. Biochem Pharmacol 1977; 26: 307-11.
BOTTCHER I, SCHWEIZER A, GLATT M, WENER H: A sulphonamidiindanone cGP 28237 (ZK 34228), a novel non-steroidal antiinflammatory agent without gastrointestinal ulcerogenicity in rats. Drugs Under Experimental and Clinical Research 1987; 13: 237-45.
SMITH RL, KAJIYAMA G, LANE N: Nonsteroidal antiinflammatory drugs: effects on normal and interleukin 1 treated human articular chondrocyte metabolism in vitro. J Rheumatol 1995; 22: 1130-7.
PELLETIER J-P, MINEAU F, FERNANDES J et al.: Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Clin Exp Rheumatol 1997; 15: 393-8.
NIETFIELD JJ, WILBRINK B, HELLE M et al.: Interleukin-1 induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 1990; 33: 818-26.
LOTZ M, GUERNE P: Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteases-1/Erythroid potentiating activity (TIMP-1/EPA). J Biol Chem 1991; 266: 2017-20.
